Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEUS ziltivekimab outcomes study in cardiovascular disease, chronic kidney disease, and inflammation
NL-OMON60080Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease, chronic kidney disease (CKD) and chronic inflammation comparing Ziltivekimab plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Time to first occurrence of 3-point major adverse cardiovascular events. Started Oct 2021; status: completed.
02
Drugs
ziltivekimab
03
Conditions
atherosclerotic diseasechronic kidney disease (CKD)chronic inflammation
Beyond the preview
Go deeper on NL-OMON60080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60080.